An association between membranous nephropathy and malignant tumors has been known for decades.
1 It was hypothesized that circulating, preformed immune complexes containing tumor antigens deposit in the glomeruli and induce membranous nephropathy; however, this hypothesis no longer appears to explain how subepithelial immune deposition occurs.
2 The in situ binding of antibodies to endogenous antigens, which is strongly supported by the characterization of phospholipase A
2 receptor 1 and thrombospondin type-1 domain-containing 7A (THSD7A) as podocyte antigens in membranous nephropathy, constitutes the most probable established mechanism for the formation of subepithelial deposits of immune complexes.
3,4 It is unclear whether the initial recognition of antigens that leads to the formation of high-affinity antibodies occurs within the kidney or in other tissues, including malignant tumors. Antibodies that are produced in response to nonrenal targets may recognize the same or related molecules expressed on podocytes through a mechanism known as molecular mimicry.